We deliver fully integrated, GMP-aligned turnkey engineering solutions dedicated to antibody-drug conjugate (ADC) manufacturing facilities, covering clinical pilot production and commercial-scale industrial plants. Our full-service scope encompasses regulatory-compliant master planning, high-containment cleanroom zoning, independent cytotoxic process suite design, upstream antibody production layout, downstream conjugation & purification workflow optimization, and complete utility & validation system deployment. Tailored for ADC’s unique manufacturing challenges—including potent cytotoxic drug handling, strict cross-contamination prevention, precise conjugation consistency and residual impurity control—our process-embedded turnkey infrastructure enables safe, stable and audit-ready production for global ADC therapeutic development and commercialization.
Our ADC plant engineering is built upon core philosophies of high-level biosafety containment, segregated cytotoxic workflow, precise process reproducibility and risk-based operational isolation. We implement fully independent negative-pressure suites, dedicated material circulation routes and exclusive waste inactivation systems to isolate potent payload processing, antibody conjugation and final formulation areas, eliminating cross-contamination and operator exposure risks. Optimized low-shear fluid paths and precisely controlled process environments stabilize critical conjugation reactions and batch consistency, while validated CIP/SIP containment structures eradicate residual cytotoxic contaminants. Modular layout design supports flexible ADC pipeline iteration and phased capacity expansion.
All facility design criteria, containment specifications and process configurations fully comply with FDA, EMA Annex 1, ICH Q-series and ISPE guidelines for potent cytotoxic biopharmaceutical manufacturing. We embed full 21 CFR Part 11 data integrity architectures and real-time environmental monitoring systems to ensure complete traceability of containment status, process parameters and batch records. Every engineering module is validated for cytotoxic safety control, residual risk mitigation and batch quality consistency, maintaining continuous inspection readiness for global GMP audits, clinical submissions and cross-border ADC product licensing.
We provide end-to-end turnkey engineering services covering pre-project feasibility and risk assessment, conceptual and detailed engineering design, high-containment cleanroom construction, system integration, commissioning and full IQ/OQ/PQ qualification documentation handover. Our single-source delivery model unifies safety containment, process performance and regulatory compliance, minimizing project coordination risks and post-construction remediation costs. Clients obtain inherently safe, highly reproducible and regulation-ready ADC manufacturing facilities to accelerate clinical translation, stabilize commercial production quality and strengthen competitive advantages in the global targeted therapy market.
